US Stock MarketDetailed Quotes

URGN UroGen Pharma Ltd

Watchlist
  • 9.460
  • +0.170+1.83%
Close Feb 28 16:00 ET
  • 9.460
  • 0.0000.00%
Post 20:01 ET
399.21MMarket Cap-3.13P/E (TTM)

UroGen Pharma Ltd Key Stats

UroGen Pharma Ltd Q4 2024 Estimates Date

Currency:USDMar 10, 2025

Estimate YoY
Revenue
25.25M
+7.30%
EPS
-0.68
+5.79%
Buy

Feb 28, 2025

UroGen Pharma Ltd Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 6 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 21.221M--
Mar 10, 20252024/Q4-- / 25.249M--
Nov 6, 20242024/Q325.204M / 24.204M--
Aug 13, 20242024/Q221.848M / 23.963M--
May 13, 20242024/Q118.781M / 21.391M--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 21.221M--
Mar 10, 20252024/Q4-- / 25.249M--
Nov 6, 20242024/Q325.204M / 24.204M--
Aug 13, 20242024/Q221.848M / 23.963M--
May 13, 20242024/Q118.781M / 21.391M--

Unlock Free Earnings Estimates

UroGen Pharma Ltd Earnings Reports

Read more

Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.

Analysis

Analyst Rating

Updated: Feb 28, 2025

Buy

  • Buy

    100.00%
  • Hold

    0.00%
  • Sell

    0.00%

Price Target

No Data